|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Medtronic Endovascular |
|---|---|
| Collaborator: |
Medtronic |
| Information provided by: | Medtronic Endovascular |
| ClinicalTrials.gov Identifier: | NCT00805948 |
Purpose
The purpose of this study is to evaluate the long-term safety and effectiveness of the Talent Thoracic Stent Graft System for treatment of descending thoracic aneurysms (DTA)following U.S. market approval.
| Condition | Intervention | Phase |
|---|---|---|
|
Thoracic Aortic Aneurysms |
Device: Talent Thoracic Stent Graft System |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Descending Thoracic Aortic Aneurysm Endovascular Repair Post-approval Study (THRIVE) |
| Estimated Enrollment: | 256 |
| Study Start Date: | January 2009 |
| Estimated Study Completion Date: | July 2019 |
| Estimated Primary Completion Date: | February 2019 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Test
Patients diagnosed with a descending thoracic aortic aneurysm are considered candidates for the endovascular repair, per the FDA approved IFU.
|
Device: Talent Thoracic Stent Graft System
endovascular repair of descending thoracic aneurysms using the Talent Thoracic Stent Graft System.
Other Name: Talent Thoracic Stent Graft System
|
A descending thoracic aneurysm is a bulge in the aorta. The aorta is a large blood vessel that carries blood away from your heart to organs in the rest of your body. Your aneurysm is caused by a weakening in the artery wall. If left untreated, this bulge may continue to grow larger and may ultimately rupture (break open) or extend in size to seriously affect other major arteries in the area. In this clinical study the Talent Thoracic Stent Graft will be placed inside your aorta to block the weakened part of the artery wall from the circulatory system.
Medtronic Vascular submitted a Pre-Market Application (PMA P070007) to the FDA on February 28, 2007, and received market approval for the Talent Stent Graft System on June 5, 2008. As a condition of approval, the FDA has requested a post-market trial. In collaboration with the FDA, Medtronic has designed a post-approval study to document the long-term performance of the Talent Stent Graft System under post market conditions.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: appropriate anatomy for elective repair of the descending thoracic aortic aneurysm
Exclusion Criteria:
Contacts and Locations| Contact: Diane Rooney, MS, MBA | rs.medtroniccardiovascularclinicaltrials@medtronic.com |
Show 26 Study Locations
More Information
| Responsible Party: | Diane Rooney, Senior Clinical Research Specialist, Medtronic Endovascular |
| ClinicalTrials.gov Identifier: | NCT00805948 History of Changes |
| Other Study ID Numbers: | Investigational Plan #109 |
| Study First Received: | December 8, 2008 |
| Last Updated: | January 25, 2012 |
| Health Authority: | United States: Institutional Review Board |
|
thoracic aneurysm thoracic aortic aneurysms TEVAR Talent Thoracic Stent Graft |
|
Aneurysm Aortic Aneurysm Aortic Aneurysm, Thoracic |
Vascular Diseases Cardiovascular Diseases Aortic Diseases |